ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.Antimicrobial resistance and infection control · 2022Pooled it
- Carbapenem resistance and mortality in pediatric Acinetobacter bloodstream infections: determinants from a 12-year tertiary-care cohort study.European journal of pediatrics · 2026Article
- The global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2025Review
- Emergence of NDM-1- and OXA-23-Co-ProducingMicroorganisms · 2025Article
- In Vitro Elimination of Highly Multidrug-Resistant Bacteria by the Lactic Acid Bacterial Drug Candidate ILP100.Infectious diseases and therapy · 2025Article
- Regional distribution of carbapenemase-producing Acinetobacter baumannii isolates in southern Spain (Andalusia).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.Scientific reports · 2025Article
- Global emergence of double and multi-carbapenemase producing organisms: epidemiology, clinical significance, and evolutionary benefits on antimicrobial resistance and virulence.Microbiology spectrum · 2024Article
- Molecular epidemiology and clinical significance of carbapenemase genes in carbapenem-resistant Acinetobacter baumannii isolates in southern Poland.Polish archives of internal medicine · 2024Article
- The Impact of COVID-19 on Multidrug-Resistant Bacteria at a Slovenian Tertiary Medical Center.Antibiotics (Basel, Switzerland) · 2024Article
- The molecular detection of carbapenem markers with a two-levels amplification screening protocol: epidemiological and resistome insights.Frontiers in microbiology · 2024Article
- Targeting virulence regulation to disarmVirulence · 2022Article
- Clonal diversity ofIJID regions · 2022Article
- Large increase in bloodstream infections with carbapenem-resistantEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Increasing number of cases and outbreaks caused byEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Is It Possible to Eradicate Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- CipA mediates complement resistance ofFrontiers in immunology · 2022Article
- A Study in a Regional Hospital of a Mid-Sized Spanish City Indicates a Major Increase in Infection/Colonization by Carbapenem-Resistant Bacteria, Coinciding with the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2021Article
- Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-ResistantFrontiers in cellular and infection microbiology · 2021Article
- Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance?Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To update information on the epidemiological situation and national capacity for detection, surveillance and containment of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.